Clincosm LogoSign in Get a demo

Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT00181792
Collaborator
(none)
70
Enrollment
1
Location
51
Duration (Months)
1.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The researchers will study 100 families over three years, each with a child (proband) between the ages of 12-17, with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of ADHD. The researchers hypothesize smoking will be familial and ADHD probands with a family history of tobacco use will be at increased risk for early initiation and persistence of smoking, compared to ADHD probands with no family history of tobacco use.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    As Attention Deficit Hyperactivity Disorder (ADHD) is a documented risk factor for smoking in adolescents, and as theoretical considerations suggest that ADHD and tobacco use may share common underlying mechanisms, the proposed study looks to examine the association between smoking and ADHD. Since both ADHD and smoking are known to be familial disorders, one approach to examine the nature of the association between the two disorders is to conduct a familial risk analysis comparing ADHD youth who smoke and ADHD youth who don't smoke. Another approach is to conduct a genetic study, to identify candidate genes associated with nicotine abuse and dependence in ADHD youth and relatives.

    This study includes:

    1. assessment of psychopathology and substance use/dependence,

    2. assessment of the family environment, and

    3. assessment of molecular genetics in 100 families with at least one child (proband) between the ages of 12-17 with a DSM-IV diagnosis of ADHD.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    70 participants
    Observational Model:
    Family-Based
    Official Title:
    Family Risk Analysis of Substance Use in ADHD Youth Treated With Concerta
    Study Start Date :
    May 1, 2005
    Actual Primary Completion Date :
    Aug 1, 2009
    Actual Study Completion Date :
    Aug 1, 2009

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      6 Years to 55 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      Yes
      Inclusion Criteria:
      • First-degree relative between the ages of 6-55 years of a family member (proband) between the ages of 12-17 with the DSM-IV diagnosis of ADHD

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Massachusetts General Hospital Cambridge Massachusetts United States 02138

      Sponsors and Collaborators

      • Massachusetts General Hospital

      Investigators

      • Principal Investigator: Paul Hammerness, MD, Massachusetts General Hospital

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Paul Hammerness, MD, Assistant Professor Psychiatry, Massachusetts General Hospital
      ClinicalTrials.gov Identifier:
      NCT00181792
      Other Study ID Numbers:
      • 2005-P-000278
      First Posted:
      Sep 16, 2005
      Last Update Posted:
      May 4, 2012
      Last Verified:
      May 1, 2012
      Keywords provided by Paul Hammerness, MD, Assistant Professor Psychiatry, Massachusetts General Hospital
      ADHD
      smoking
      familial risk
      Additional relevant MeSH terms:
      Substance-Related Disorders

      Study Results

      No Results Posted as of May 4, 2012